---
title: "TG Therapeutics: Buy Rating Reaffirmed as Briumvi Schizophrenia Trial Adds Upside Optionality; $70 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291822993.md"
description: "H.C. Wainwright analyst Emily Bodnar reaffirmed a Buy rating on TG Therapeutics (TGTX) with a $70 price target, citing the upside potential of Briumvi's Phase 2 schizophrenia trial as an optionality that does not impact current valuation. Jefferies also assigned a Buy rating with an $83 target. The bullish stance is supported by mechanistic rationale for B-cell depletion in psychiatric disorders and an attractive risk/reward profile."
datetime: "2026-07-06T15:25:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291822993.md)
  - [en](https://longbridge.com/en/news/291822993.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291822993.md)
generator: "portal-rs"
---

# TG Therapeutics: Buy Rating Reaffirmed as Briumvi Schizophrenia Trial Adds Upside Optionality; $70 Price Target Unchanged

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on TGTX stock, giving a Buy rating on June 21.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Emily Bodnar has given his Buy rating due to a combination of factors, including TG Therapeutics’ strategic move to explore Briumvi in treatment-resistant schizophrenia while maintaining its core multiple sclerosis franchise. The new Phase 2 study represents a relatively low-cost way to test B-cell depletion in a high-need psychiatric indication, offering meaningful upside without being required to support the current valuation.

She notes that prior proof-of-concept data with rituximab in schizophrenia spectrum disorders provide a mechanistic and clinical rationale, and Briumvi’s more complete and rapid B-cell depletion could translate into improved and more durable patient outcomes. At the same time, her financial model and $70 price target do not assume any contribution from the schizophrenia program, so positive signals from this trial would add incremental value rather than being needed to justify the Buy rating, keeping the risk/reward profile attractive for investors.

In another report released on June 21, Jefferies also assigned a Buy rating to the stock with a $83.00 price target.

### Related Stocks

- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics](https://longbridge.com/en/news/296647082.md)
- [TG Therapeutics (NASDAQ:TGTX) Trading 10.1% Higher   - Should You Buy?](https://longbridge.com/en/news/296638172.md)
- [Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study](https://longbridge.com/en/news/296635926.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)
- [TG Therapeutics initiates Phase 2 trial of Briumvi in treatment-resistant schizophrenia patients](https://longbridge.com/en/news/291796468.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**